These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 19615053)
1. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053 [TBL] [Abstract][Full Text] [Related]
2. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Meloni F; Caporali R; Marone Bianco A; Paschetto E; Morosini M; Fietta AM; Patrizio V; Bobbio-Pallavicini F; Pozzi E; Montecucco C Sarcoidosis Vasc Diffuse Lung Dis; 2004 Jun; 21(2):111-8. PubMed ID: 15281432 [TBL] [Abstract][Full Text] [Related]
3. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. Sfriso P; Cozzi F; Oliviero F; Caso F; Cardarelli S; Facco M; Fittà C; Del Rosso A; Matucci-Cerinic M; Punzi L; Agostini C Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S71-5. PubMed ID: 22691213 [TBL] [Abstract][Full Text] [Related]
4. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis. Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398 [TBL] [Abstract][Full Text] [Related]
6. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Kowal-Bielecka O; Kowal K; Highland KB; Silver RM Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649 [TBL] [Abstract][Full Text] [Related]
8. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Vasakova M; Sterclova M; Kolesar L; Slavcev A; Pohunek P; Sulc J; Skibova J; Striz I Scand J Immunol; 2009 Mar; 69(3):268-74. PubMed ID: 19281539 [TBL] [Abstract][Full Text] [Related]
9. Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis. Becker MO; Radic M; Schmidt K; Huscher D; Riedlinger A; Michelfelder M; Meisel C; Ewert R; Burmester GR; Riemekasten G Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):274-284. PubMed ID: 32476963 [TBL] [Abstract][Full Text] [Related]
10. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. Wu M; Baron M; Pedroza C; Salazar GA; Ying J; Charles J; Agarwal SK; Hudson M; Pope J; Zhou X; Reveille JD; Fritzler MJ; Mayes MD; Assassi S Arthritis Rheumatol; 2017 Sep; 69(9):1871-1878. PubMed ID: 28575534 [TBL] [Abstract][Full Text] [Related]
11. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses. Fields A; Potel KN; Cabuhal R; Aziri B; Stewart ID; Schock BC Thorax; 2023 Aug; 78(8):799-807. PubMed ID: 36261273 [TBL] [Abstract][Full Text] [Related]
12. Elevated α-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease. Sakamoto N; Ishimoto H; Kakugawa T; Satoh M; Hasegawa T; Tanaka S; Hara A; Nakashima S; Yura H; Miyamura T; Koyama H; Morita T; Nakamichi S; Obase Y; Ishimatsu Y; Mukae H BMC Pulm Med; 2018 Mar; 18(1):44. PubMed ID: 29530007 [TBL] [Abstract][Full Text] [Related]
13. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. De Santis M; Bosello SL; Peluso G; Pinnelli M; Alivernini S; Zizzo G; Bocci M; Capacci A; La Torre G; Mannocci A; Pagliari G; Varone F; Pistelli R; Danza FM; Ferraccioli G Clin Respir J; 2012 Jan; 6(1):9-17. PubMed ID: 21801327 [TBL] [Abstract][Full Text] [Related]
14. Bronchoalveolar Lavage Fluid Reflects a T Friedmann D; Unger S; Keller B; Rakhmanov M; Goldacker S; Zissel G; Frye BC; Schupp JC; Prasse A; Warnatz K Front Immunol; 2020; 11():616832. PubMed ID: 33613543 [TBL] [Abstract][Full Text] [Related]
15. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031 [TBL] [Abstract][Full Text] [Related]